BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/24/2021 9:48:20 AM | Browse: 573 | Download: 765
Publication Name World Journal of Gastroenterology
Manuscript ID 69541
Country Japan
Received
2021-07-06 04:39
Peer-Review Started
2021-07-06 04:44
To Make the First Decision
Return for Revision
2021-07-26 03:49
Revised
2021-09-27 09:13
Second Decision
2021-12-14 03:39
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2021-12-22 23:30
Articles in Press
2021-12-22 23:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2021-12-23 02:47
Publish the Manuscript Online
2021-12-24 09:48
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity
Manuscript Source Unsolicited Manuscript
All Author List Yuki Fujimoto, Kosuke Kaji, Norihisa Nishimura, Masahide Enomoto, Koji Murata, Soichi Takeda, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane and Hitoshi Yoshiji
ORCID
Author(s) ORCID Number
Yuki Fujimoto http://orcid.org/0000-0002-5046-0588
Kosuke Kaji http://orcid.org/0000-0002-1822-6759
Norihisa Nishimura http://orcid.org/0000-0002-6295-3283
Masahide Enomoto http://orcid.org/0000-0001-8980-4758
Koji Murata http://orcid.org/0000-0001-5149-2437
Soichi Takeda http://orcid.org/0000-0001-6457-2954
Hiroaki Takaya http://orcid.org/0000-0002-4990-7573
Hideto Kawaratani http://orcid.org/0000-0002-4361-0592
Kei Moriya http://orcid.org/0000-0002-2878-8296
Tadashi Namisaki http://orcid.org/0000-0002-3158-5318
Takemi Akahane http://orcid.org/0000-0002-6675-0475
Hitoshi Yoshiji http://orcid.org/0000-0002-5243-8544
Funding Agency and Grant Number
Corresponding Author Kosuke Kaji, MD, PhD, Doctor, Lecturer, Senior Researcher, Department of Gastroenterology, Nara Medical University, 840, Shijo-cho, Kashihara 6348521, Nara, Japan. kajik@naramed-u.ac.jp
Key Words Liver fibrosis; Intestinal permeability; Alcoholic liver disease; Lipopolysaccharide; Toll-like receptor; Tight junction protein
Core Tip Gut-derived lipopolysaccharide dictates the progression of alcoholic liver disease (ALD) hence the maintenance of intestinal barrier integrity has attracted attention for the treatment of ALD. This study elucidates the preventive effect of combined zinc supplementation and rifaximin from ALD-related liver fibrosis induced by ethanol plus carbon tetrachloride in mice. This effect is involved in the multifaceted regulatory functions that maintain intestinal barrier integrity and reduce hepatic lipopolysaccharide exposure, thereby, leading to Kupffer cell expansion and hepatic stellate cell activation by inhibiting the toll-like receptor 4 pathway, highlighting that this regimen may represent a potential novel strategy against ALD-related liver fibrosis.
Publish Date 2021-12-24 09:48
Citation Fujimoto Y, Kaji K, Nishimura N, Enomoto M, Murata K, Takeda S, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. World J Gastroenterol 2021; 27(48): 8323-8342
URL https://www.wjgnet.com/1007-9327/full/v27/i48/8323.htm
DOI https://dx.doi.org/10.3748/wjg.v27.i48.8323
Full Article (PDF) WJG-27-8323.pdf
Full Article (Word) WJG-27-8323.docx
Manuscript File 69541_Auto_Edited-A.docx
Answering Reviewers 69541-Answering reviewers.pdf
Audio Core Tip 69541-Audio core tip.mp3
Biostatistics Review Certificate 69541-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 69541-Conflict-of-interest statement.pdf
Copyright License Agreement 69541-Copyright license agreement.pdf
Institutional Animal Care and Use Committee Approval Form or Document 69541-Institutional animal care and use committee statement.pdf
Institutional Review Board Approval Form or Document 69541-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 69541-Language certificate.pdf
Supplementary Material 69541-Supplementary material.pdf
Peer-review Report 69541-Peer-review(s).pdf
Scientific Misconduct Check 69541-Bing-Liu M-2.png
Scientific Editor Work List 69541-Scientific editor work list.pdf